Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Vanderbilt Muscle Study Vanderbilt University has registered a trial to preserve muscle in elderly individuals starting semaglutide, a medication for type 2 diabetes and weight loss. On August 12, a phase 2 trial record appeared in ClinicalTrials.gov, involving 90 people aged 65-85 with type 2 diabetes, starting semaglutide, who will be randomly assigned to receive either calcium HMB with vitamin D3 or a placebo for six months. During weight loss, lean tissue, including skeletal muscle, may also decrease. Muscle is essential for strength, walking, and independent living in older adults. In this trial, treating physicians will prescribe and manage semaglutide therapy, while the research team compares the supplement to a placebo during the first six months of treatment. The trial will assess changes in lean body mass, measured using DXA scans, as the primary outcome. Researchers will also evaluate hand and leg strength, six-minute walk distance, gait, and daily activity. Quantitative CT scans will provide data on muscle volume and composition, allowing researchers to correlate changes in body composition with strength and movement. 🔗 Read original →